Title:  Treatments for spinal muscular atrophy

United States Patent:  6,376,508

Assignee:  Academia Sinica (Taipei, TW)

Filed:  December 13, 2000

The invention features a method of modulating SMN exon 7 expression in a subject by administering a histone deacetylase inhibitor.

SUMMARY OF THE INVENTION

The invention is based on the discovery that different classes of compounds have been identified, using new methods, as being useful in the modulation of SMN exon 7 gene expression, and therefore as being useful in the treatment of SMA. It has also been discovered that cells harvested from SMA patients and transgenic animals having particular genotypes and phenotypes are useful in the new screening methods.

Accordingly, the invention features a method for modulating SMN gene expression in a subject. The method includes administering to the subject an amount of a histone deacetylase inhibitor sufficient to increase the expression level of SMN exon 7 in a cell of the subject, relative to a reference expression level of SMN exon 7.

Histone deacetylase inhibitors include butyrates (e.g., sodium butyrate, arginine butyrate, and butyric acid); trapoxin; and trichostatin A.

The reference level of SMN exon 7 can be the level in a cell of the subject prior to treatment, or a cell that has not been treated. The method can increase the expression level of SMN exon 7 by at least about 30%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or greater. Alternatively, the increase can be measured by the ratio of transcripts containing exon 7 to those lacking exon 7. This ratio can be increased by at least about 30%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or greater.

Also featured is a method of treating spinal muscular atrophy in a subject. The method includes administering to the subject a histone acetylase inhibitor in an amount sufficient to ameliorate a symptom of spinal muscular atrophy, e.g., a dosage described below. The subject can be a mammal, e.g., a human. A human subject can be homozygous for mutations in SMN1.

The subject can be a fetus that is treated in utero, e.g., by administering the histone acetylase inhibitor to the fetus directly or indirectly (e.g., via the mother).

As used herein, the term "transgene" refers to a nucleic acid sequence (e.g., encoding one or more human proteins), which is inserted by artifice into a cell. The transgene is integrated into a chromosomal genome. A transgenic sequence can be partly or entirely species-heterologous, i.e., the transgenic sequence, or a portion thereof, can be from a species which is different from the cell into which it is introduced. A transgenic sequence can be partly or entirely species-homologous, i.e., the transgenic sequence, or a portion thereof, can be from the same species as is the cell into which it is introduced. If a transgenic sequence is homologous (in the sequence sense or in the species-homologous sense) to an endogenous gene of the cell into which it is introduced, then the transgenic sequence has one or more of the following characteristics: it is designed for insertion, or is inserted, into the cell's genome in such a way as to alter the sequence of the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the endogenous gene or its insertion results in a change in the sequence of the endogenous gene); it includes a mutation, e.g., a mutation which results in misexpression of the transgenic sequence; by virtue of its insertion, it can result in misexpression of the gene into which it is inserted, e.g., the insertion can result in a knockout of the gene into which it is inserted. A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid sequences, such as introns, that may be necessary for a desired level or pattern of expression of a selected nucleic acid. A transgene can provide an antisense transcript or a sense transcript, e.g., a transcript encoding a protein.

As used herein, the term "transgenic cell" refers to a cell containing a transgene.

As used herein, a "transgenic animal" is a non-human animal in which one or more (e.g., all) of the cells of the animal contain a heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques known in the art. The transgene can be introduced into the cell directly, indirectly by introduction into a precursor of the cell, or by way of deliberate genetic manipulation, such as by microinjection, transformation, electroporation, lipofection, or infection with a recombinant virus. In one example, where the transgene is introduced indirectly, the transgene is introduced into a cultured cell, and the nucleus of the cultured cell or of a descendant of the cultured cell is microinjected into an enucleated oocyte to produce a nucleated oocyte which develops into an animal.

As used herein, a "disruption" in reference to an endogenous gene refers to any type of mutation that inactivates an endogenous gene, an exon thereof, or the amino acid sequence encoded by the endogenous gene or exon thereof. Consequently, the mutation can be a deletion of the disrupted gene or portion thereof, a mutation that causes inappropriate splicing (including abolishment of splicing), and/or and insertion into the disrupted gene or portion thereof.

In reference to subjects (e.g., animal models of SMA, e.g., a transgenic mouse model, and patients), a symptom of SMA is selected from: lethality before birth, before postnatal day 10, or before 4 weeks of age; decreased fetal movement; lethargy; loss or depression of muscular reflexes (e.g., areflexia, loss of gag reflex); hand tremors; peripheral neuropathies; large amplitude, prolonged, polyphasic discharges on active muscle contraction as detected by EMG (electromyography); myopathies; muscular weakness (e.g., weakness in the pelvic girdle, arms, facial muscles, instability of walking gait, paralysis of hind limbs, tongue fasciculation, and atrophy); myasthenia; hypertrophied muscle bundles (e.g., pseudohypertrophy of the calves); fat infiltration in muscle bundles; fibrosis in muscle bundles; necrosis in muscle bundles; muscular dystrophies; atrophy of muscle bundles (e.g., in tail, trunk, or limbs); decreased diameter of muscle fibers in the tail, trunk, or limbs; shorter and enlarged tails; chronic necrosis of the tail tip; subcutaneous edema; and reduced furry coat hair (see, e.g., Gendron and MacKenzie (1999) Current Op. in Neurology 12:137-142).

The skilled artisan can readily determine which of the list of symptoms would apply to a particular animal model. For example, a shortened tail is relevant only to those animals having a tail, and hand tremors are only relevant to those animals having a hand (e.g., a primate.). A symptom for type 1 spinal muscular atrophy in a mouse includes lethality before postnatal day 10, reduced furry coat hair, and a shortened and enlarged tail.

A used herein, the term "modulating" refers to a change in level, either an increase or a decrease. The change can be detected in a qualitative or quantitative observation. If a quantitative observation is made, and if a comprehensive analysis is performed over a plurality of observations, one skilled in the art can apply routine statistical analysis to identify modulations where a level is changed and where the statistical parameter, the p value, is less than 0.05.

As used herein, "full-length SMN gene expression" or "expression level of SMN exon 7" refers to a scenario where an SMN gene is transcribed and the resulting transcripts contain exon 7 of an SMN gene. Specifically, it is of no consequence whether the exon 7-containing transcript is transcribed from the human SMN1 gene or from the human SMN2 gene. Transcripts containing SMN exon 7 are translated into the 294 amino acid SMN polypeptide. The amino acid sequence of the 294 amino acid SMN polypeptide is described in GenBank entry "GI:624186." The nucleic acid sequence of SMN exon 7 is the sequence contained between about nucleotides 868 and 921 of GenBank entry "GI:624185." The identify of the sixth base of exon 7 can be C (cytosine) if the transcript is derived from SMN1 or U (uracil) if the transcript is derived from SMN2. Exon 7 expression can be analyzed in cells in which SMN1 is deleted or mutated. Thus, the relevant SMN exon 7 sequence contains a uracil at position 873 while the remainder of the sequence is as recited from about nucleotides 868 to 921 of GenBank entry "GI:624185."

As used herein, a "histone deacetylase inhibitor" is a molecule which decreases the activity of a histone deacetylase enzyme in an in vitro assay. An assay for inhibition in vitro is described in Yoshida et al. ((1990) J. Biol. Chem. 265:17174-17179). A pure or semi-pure sample of eukaryotic histone deacetylase is obtained from FM3A tissue culture cells (e.g., available from Dr. Ayusawa, University of Tokyo, Japan). Cells are homogenized in buffer A (15 mM potassium phosphate, pH 7.5, 5% glycerol and 0.2 mM EDTA). The homogenate is centrifuged; then nuclei are pelleted by further centrifugation, and ruptured in buffer containing 1 M (NH₄)₂ SO₄. The ruptured nuclei are sonicated and clarified by centrifugation. Histone deacetylase is precipitated from this fraction by increasing the (NH₄)₂ SO₄ concentration to 3.5 M. The pellet is resuspended in buffer A, dialyzed against the same, loaded on a DEAE-cellulose column, and eluted with a linear NaCl gradient (0-0.6 M). The fraction eluting between 0.2 and 0.3 M NaCl and containing histone deacetylase is identified. Meanwhile, [³H] acetyl-labeled histones are obtained from FM3A cells grow in the presence of 0.5 mCi/ml [³H] acetate and 5 mM sodium butyrate. Histones are extracted from the cells using the method of Cousens et al. ((1979) J. Biol. Chem. 254:1716-1723). Assay tubes are prepared either containing the inhibitor molecule or containing a mock treatment, e.g., the solution and/or buffers in which the inhibitor is prepared. Then, 4 .mu.l of [³H] acetyllabeled histones and 96 .mu.l of histone deacetylase are added. The tube is incubated at 37^oC. for 10 minutes. The reaction is stopped with 10 .mu.l of concentrated HCl. Released [³H] acetic acid is extracted with 1 ml of ethyl acetate; 0.9 ml of the solvent layer is added to 5 ml of toluene or other acceptable scintillation solution and counted in a liquid scintillation counter. An inhibitor of histone deacetylase will decrease the amount of released [³H] acetic acid relative to a control, e.g., by about 30%, 40%, 60%, 80%, 90% or greater.

Claim 1 of 15 Claims

What is claimed is:

1. A method for modulating SMN gene expression in a subject, the method comprising administering to the subject an amount of a histone deacetylase inhibitor sufficient to increase the expression level of SMN exon 7 in a cell of the subject, relative to a reference expression level of SMN exon 7.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.